First patient marks Polyrizon’s transition into a clinical-stage company.

The U.S clinical study is designed to evaluate the efficacy, safety and tolerability of the NASARIX (PL-14) Allergy Blocker in patients with seasonal allergic rhinitis

Raanana, Israel, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a clinical- stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the enrollment of the first patient in its U.S. clinical study to evaluate NASARIX (PL-14), the Company’s investigational Allergy Blocker, in patients with seasonal allergic rhinitis (SAR).

The enrollment of the first patient represents a significant milestone for Polyrizon and marks the Company’s transition into the clinical stage of development.